Health Care
CSL Ltd (CSL)
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Market Cap
A$140B
Shares on Issue
0.48B
Price Chart (TradingView)
AI Analysis
CSL's plasma network provides scale advantages, supporting margin recovery as collection volumes normalize. Pipeline momentum in immunology and hematology broadens the long-term growth profile.
The vaccine segment adds diversification, with steady demand from global immunization programs. Execution on R&D and manufacturing expansion will remain in focus for investors.
Bull Case
- • Plasma volume recovery supports earnings growth.
- • Deep R&D pipeline drives new product launches.
- • Global manufacturing footprint enhances resilience.
Bear Case
- • Competition in plasma therapies could pressure pricing.
- • Regulatory delays may slow product approvals.
- • High R&D spend can weigh on near-term margins.
Recent Announcements
Quarterly Activities Report
Highlights production updates, capital allocation priorities, and FY guidance commentary.
Investor Presentation
Strategic outlook with market positioning and growth pipeline.
FAQs
What does CSL produce?
CSL makes plasma-derived therapies, vaccines, and specialty biologic medicines.
Where does CSL operate?
CSL operates globally with major facilities in Australia, the US, and Europe.
What drives CSL earnings?
Plasma collection volumes, product pricing, and pipeline execution are key drivers.
Key Metrics
Compare ASX Brokers
Find the best trading platform for your needs. We review fees, features, and research tools.
AlphaTrade
$0 brokerage on ETFs
MarketPilot
Advanced research suite
Coastline
Low FX fees
Harbour
Pro-level charting
Sponsored links. We may receive compensation if you open an account.